Valuation: Supernus Pharmaceuticals, Inc.

Market Cap 2.77B 2.43B 2.27B 2.09B 3.9B 265B 4B 26.94B 10.54B 131B 10.4B 10.18B 454B P/E 2026 *
107x
P/E 2027 * 31.9x
Enterprise Value 2.77B 2.43B 2.27B 2.09B 3.9B 265B 4B 26.94B 10.54B 131B 10.4B 10.18B 454B EV / Sales 2026 *
3.19x
EV / Sales 2027 * 2.71x
Free-Float
95.54%
Yield 2026 *
-
Yield 2027 * -
1 day-2.14%
1 week-0.51%
Current month+0.41%
1 month-0.21%
3 months-3.81%
6 months-4.81%
Current year-6.04%
1 week 45.84
Extreme 45.8425
48.45
1 month 45.84
Extreme 45.8425
51.37
Current year 42.45
Extreme 42.45
59.68
1 year 32.83
Extreme 32.83
59.68
3 years 21.99
Extreme 21.99
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 64 21/12/2005
Director of Finance/CFO 67 22/08/2021
Chief Tech/Sci/R&D Officer 54 31/12/2016
Director TitleAgeSince
Director/Board Member 64 21/12/2005
Chairman 81 09/08/2016
Director/Board Member 80 15/11/2010
Date Insider Type Main position Quantity % Market Cap.
16/03/26 Fiscal year

Chief Technology Officer

321,750 0.5738%
13/03/26 Others

Founder

60,000 0.1070%
12/03/26 Sell

Director

5,369 0.0096%
Change 5-day change 1-year change 3-year change Capi.($)
-2.17%-0.51%+39.61%+52.17% 2.77B
-0.72%+3.01%+58.91%+23.12% 326B
-0.38%+6.28%+40.07%+92.53% 9.9B
+1.77%+1.73%+5.03%+0.41% 8.49B
-4.91%-2.58%-24.55%-7.47% 4.28B
-0.19%-4.07%-9.49%+1.66% 3.61B
-0.57%+1.01%-41.56%+6.52% 3.63B
+6.83%+1.97%-1.69%-4.68% 2.1B
+0.85%-5.42%-19.38%+19.69% 1.78B
+1.05%-0.11%-22.60%-20.18% 1.71B
Average +0.17%-0.38%+2.44%+16.38% 36.38B
Weighted average by Cap. -0.71%+4.59%+53.22%+23.58%

Financials

2026 *2027 *
Net sales 867M 762M 711M 653M 1.22B 83.06B 1.25B 8.43B 3.3B 41.1B 3.26B 3.19B 142B 1.02B 899M 839M 770M 1.44B 97.98B 1.48B 9.95B 3.89B 48.48B 3.84B 3.76B 168B
Net income 25.92M 22.78M 21.26M 19.51M 36.53M 2.48B 37.43M 252M 98.6M 1.23B 97.33M 95.22M 4.25B 92.99M 81.71M 76.27M 70M 131M 8.91B 134M 904M 354M 4.41B 349M 342M 15.24B
Net Debt - -
Logo Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Date Price Change Volume
29/07/26 US$46.87 -1.80% 173,516
28/07/26 US$47.73 +1.60% 538,195
27/07/26 US$46.98 +1.69% 523,013
24/07/26 US$46.20 -2.10% 521,935
23/07/26 US$47.19 +0.53% 463,337
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
47.73USD
Average target price
63.50USD
Spread / Average Target
+33.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SUPN Stock